Study #2016-0896
A Phase II Multicenter Single Arm Study to Evaluate the Efficacy and Safety of Single Agent Bruton's Tyrosine Kinase Inhibitor, Ibrutinib, in Patients with Relapsed Refractory Classical Hodgkin's Lymphoma
MD Anderson Study Status
Not Accepting
Treatment Agent
Ibrutinib
Description
This phase II trial evaluates how effective 560 mg of ibrutinib taken by mouth daily is in the treatment of classical Hodgkin lymphoma which recurs or does not respond to initial treatment. Ibrutinib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth, by altering the environment around the tumor or by affecting the immune system.
Resources and Links
Phone Number: 1-877-MDA-6789
Information and next steps
Disease:
Classical Hodgkin Lymphoma, Recurrent Hodgkin Lymphoma, Refractory Hodgkin Lymphoma
Study phase:
Phase II
Physician name:
Hun Ju Lee
Department:
Lymphoma/Myeloma
For general questions about clinical trials:
1-844-737-0154
Help #EndCancer
Give Now
Donate Blood
Our patients depend on blood and platelet donations.
Shop MD Anderson
Show your support for our mission through branded merchandise.